Compare Eli Lilly And Co (LLY) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs SoFi Technologies Inc — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while SoFi Technologies Inc trades at $15.84 (market cap $20.16B). The key difference: Eli Lilly And Co is far larger — about 51.6× SoFi Technologies Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and SoFi Technologies Inc for 60 Days on average.
| LLY | SOFI | |
|---|---|---|
Market Cap | $1.04T | $20.16B |
Volume | 3,064,878 | 49,646,331 |
Sector | Health | Financials |
52-Week High | $1.28K | $32.21 |
52-Week Low | $799.57 | $15.15 |
Typical Hold Time | 93 Days | 60 Days |
Enterprise Value | $1.09T | $20.30B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
SoFi Technologies (SOFI) trades at $15.72, up 0.38% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported strong revenue growth, with 2025 revenue reaching $3.61 billion and net income of $481.32 million, though cash flow from operations remains negative. Analyst consensus is mixed with a $21.58 price target, but technical indicators signal caution.
SoFi's growth trajectory and improving profitability present long-term potential, but near-term risks include persistent negative operating cash flow, high valuation multiples, and sensitivity to interest rates. Execution on loan originations and stablecoin initiatives will be critical for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
